CompletedPhase 2NCT03816176
A Study to Evaluate Isavuconazonium Sulfate for the Treatment of Invasive Aspergillosis (IA) or Invasive Mucormycosis (IM) in Pediatric Participants
Studying Aspergillosis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Astellas Pharma Global Development, Inc.
- Principal Investigator
- Executive DirectorAstellas Pharma Global Development, Inc.
- Intervention
- Isavuconazonium sulfate(drug)
- Enrollment
- 31 enrolled
- Eligibility
- 1-17 years · All sexes
- Timeline
- 2019 – 2022
Study locations (10)
- Children's Hospital, Los Angeles, Los Angeles, California, United States
- University of California - Los Angeles, Los Angeles, California, United States
- Children's Hospital of Orange County, Orange, California, United States
- Children's National Medical Center, Washington D.C., District of Columbia, United States
- Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois, United States
- Site BE32001, Ghent, Belgium
- Site BE32002, Leuven, Belgium
- Site ES34002, Barcelona, Spain
- Site ES34003, Madrid, Spain
- Site ES34001, Madrid, Spain
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT03816176 on ClinicalTrials.govOther trials for Aspergillosis
Additional recruiting or active studies for the same condition.
- ACTIVE NOT RECRUITINGNCT07238114Liver Cirrhosis Patients With Invasive Pulmonary Aspergillosis: in Depth Understanding Clinical Host Risk FactorsUniversitaire Ziekenhuizen KU Leuven
- RECRUITINGPHASE2NCT06794554Rezafungin for Treatment of Chronic Pulmonary Aspergillosis (CPA) in Adults With Limited Treatment OptionsMundipharma Research Limited
- RECRUITINGNCT07313527PCR for Aspergillus Fumigatus in Blood and Bronchoalveolar Lavage Fluid for Monitoring Cases of Invasive Aspergillosis: What is Its Prognostic ValueUniversity Hospital, Strasbourg, France
- ACTIVE NOT RECRUITINGNCT06583512Treatment Duration of IPAPeking University People's Hospital
- RECRUITINGNCT06885905Impact of Chronic Pulmonary Aspergillosis (CPA) on Health Status and Well-beingImperial College London
- RECRUITINGNANCT06440915Study on Theraputic Drug Monitoring and Phamacokinetics of Isavuconazole in ChildrenShanghai Children's Medical Center
- RECRUITINGPHASE3NCT06447402A Trial to Compare Nebulized Amphotericin B and Nebulized Normal Saline as Maintenance in Patients With Chronic Pulmonary AspergillosisPost Graduate Institute of Medical Education and Research, Chandigarh
- RECRUITINGPHASE2NCT05653193Interferon-gamma as Adjunctive Therapy in Chronic Pulmonary Aspergillosis: a Randomised Feasibility StudyManchester University NHS Foundation Trust